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BRIEF DEFINITIVE REPORT

Zoonotic orthopoxviruses encode
a high-affinity antagonist of NKG2D
Jessica A. Campbell,1 David S. Trossman,2 Wayne M. Yokoyama,2
and Leonidas N. Carayannopoulos1
of Pulmonary and Critical Care Medicine and 2Division of Rheumatology and Howard Hughes Medical Institute,
Washington University School of Medicine, St. Louis, MO 63110

The Journal of Experimental Medicine

1Division

NK and T lymphocytes express both activating and inhibiting receptors for various members
of the major histocompatibility complex class I superfamily (MHCISF). To evade immunologic cytotoxicity, many viruses interfere with the function of these receptors, generally
by altering the displayed profile of MHCISF proteins on host cells. Using a structurally
constrained hidden Markov model, we discovered an orthopoxvirus protein, itself distantly
class I–like, that acts as a competitive antagonist of the NKG2D activating receptor. This
orthopoxvirus MHC class I–like protein (OMCP) is conserved among cowpox and monkeypox
viruses, secreted by infected cells, and bound with high affinity by NKG2D of rodents and
humans (KD  30 and 0.2 nM, respectively). OMCP blocks recognition of host-encoded
ligands and inhibits NKG2D-dependent killing by NK cells. This finding represents a novel
mechanism for viral interference with NKG2D and sheds light on intercellular recognition
events underlying innate immunity against emerging orthopoxviruses.
CORRESPONDENCE
Leonidas N. Carayannopoulos:
lcarayan@im.wustl.edu

Viral replication alters gene expression and
protein metabolism in host cells. This perturbs
the profile of proteins displayed on the plasma
membrane, labeling infected cells as abnormal
and targeting them for destruction by cytotoxic
effectors. Such perturbations fall into two categories: the display of pathogen-encoded molecules and the altered expression of host-encoded
markers, including diverse members of the MHC
class I superfamily (MHCISF). The former are
sensed using clonotypic receptors of adaptive
immunity, whereas the latter are sensed through
receptors associated with innate immunity.
NKG2D is an activating receptor of NK lymphocytes, as well as of species-specific subsets of
T lymphocytes (for review see reference 1). It
binds host-encoded members of the MHCISF
whose expression is enhanced by extracellular
signals and intracellular metabolic disturbances,
particularly those resulting from infection (for review see reference 1). Human and mouse CMV
encode MHC class I–like proteins that block cellsurface expression of NKG2D ligands (2–7). By
interfering with NKG2D-dependent responses
to infected cells, these proteins permit enhanced
replication of the virus in a hostile immunologic
environment. Conservation of the corresponding
genes by wild strains of CMV (unpublished data)
demonstrates, prima facie, the importance of
NKG2D-mediated immunity to CMV evolution.
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In this paper, we show that zoonotic orthopoxviruses (ZPXVs) encode a secreted class
I–like competitive antagonist of NKG2D, suggesting that NKG2D function also applies selective pressure to these viruses. In contrast to
CMV, ZPXVs have adapted the class I domain
fold to target the receptor rather than its ligands.
Because receptors that direct innate cytotoxicity against epidemiologically relevant orthopoxviruses remain undefined, this finding should
open new avenues of research into immunity
against these emerging pathogens.
RESULTS AND DISCUSSION
Hidden Markov model (HMM) analysis reveals
an orthopoxvirus MHC class I–like
protein (OMCP)
NKG2D ligands adopt MHC class I–like backbone folds despite low sequence identity (for
review see reference 8). The m157 protein of
mouse CMV (a ligand for the Ly49H NK receptor) probably does so as well, though the Basic
Local Alignment Search Tool heuristic fails to
align it with any mammalian member of the
MHCISF (9, 10). We hypothesized that orthopoxviruses also encoded MHCISF proteins that
remained undetected because of their extreme
sequence divergences. Indeed, uncharacterized
class I–like open reading frames in the genomes of
molluscipoxvirus, suipoxvirus, and yatapoxviruses
1311

have been predicted using local alignment methods (for review
see reference 11). To search for the former, we adapted the
profile HMM algorithm embodied in the Sequence Alignment
and Modeling (SAM) software package from the University
of California, Santa Cruz (12, 13).
To avoid bias toward classical class I sequences, we used
a seed alignment consisting only of divergent class I–like platform domains; during iterative model weighting, this was
left inviolate despite the eventual inclusion of classical class I
sequence information. To avoid alignment errors arising from
the small number of available highly divergent MHCISF
members, this seed was based on secondary structure defined
by x-ray diffraction.
A search of National Center for Biotechnology Information (NCBI) raw viral sequence data yielded high-scoring
translations encoded within the genomes of cowpox virus
(CPXV; available from GenBank/EMBL/DDBJ under accession nos. AF482758 and X94355) and monkeypox virus
(MPXV; available from GenBank/EMBL/DDBJ under accession no. NC_003310.1). None were found in the vaccinia or variola genomes. In every case, the corresponding
open reading frames lay within genomic flanking regions,
the sites of poxvirus immunomodulatory loci (for review see
reference 11). These sequences correspond to a single protein (OMCP) with four variants, the first encoded by less
virulent West African MPXV (clade-1) (14, 15), the second
encoded by the more virulent Central African MPXV (clade-2)

(14, 15), the third encoded by CPXV-GRI90, and the fourth
encoded by CPXV–Brighton Red (CPXV-BR; Fig. 1 A).
Clade-1 MPXV possess identical functional copies at both
flanks of their genomes, whereas clade-2 viruses possess only
a right-sided functional copy, with the left-sided one being a
nonfunctional fragment (not depicted). Consistent with the
proposal that CPXV-BR represents a distinct orthopoxvirus
species (16), Brighton Red OMCP is considerably more divergent from the other sequences than they are from each
other. Because of the >93% aa identity between the first three
variants, they henceforth are collectively termed OMCPMPX.
The Brighton Red variant henceforth is termed OMCPBR.
OMCP possesses a strongly predicted leader sequence,
two cysteines (Fig. 1 A), and a common potential N-linked
glycosylation site at Asn31 (CPXV-BR numbering); OMCPBR
has a second potential N-linked site at Asn107 (Fig. 1 A).
Backbone prediction using the FUGUE (17) threading algorithm assigns reasonable likelihood (z-score >5) to a class I–
like fold for OMCP. In this model, the cysteines are close in
three-dimensional space (Fig. 1 B) and are predicted to form
a disulfide bond. Neither transmembrane spans nor GPI
transamidation sites could be predicted in any reading frame
near the ends of the coding sequences, suggesting OMCP to
be a secreted protein. To test this, supernatants from both
mock-infected B-SC-1 cells as well as those infected either
with CPXV-BR or Western Reserve vaccinia virus (VV)
were screened by immunoblot for reactivity with a polyclonal

Figure 1. OMCP is likely a secreted class I–like protein. (A) Multiple
alignment of the four OMCP variants. Cysteines (C) and potential N-linked
glycosylation sites (closed circles) are indicated. (B) Backbone model of
OMCPBR derived by threading through the RAE1β structure (closed squares,
cysteines). Similar results were obtained for OMCPMPX. (C) Immunoblot of
culture media conditioned by mock-infected and CPXV-BR–infected

B-SC-1 cells suggests secretion of OMCP. (D) Immunoblot showing that
brefeldin A, but not its ethanol vehicle, prevents the appearance of
OMCPBR in supernatants from infected OP9 cells (far right lane vs. second
lane from right). Brefeldin A also causes the accumulation of OMCP in
lysates of treated cells (third lane from left).
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antiserum against recombinant OMCPBR (Fig. 1 C). Only
supernatants from CPXV-BR–infected cells reacted with the
antiserum, while neither supernatant reacted with preimmune serum. To verify that OMCP was secreted and not released from lysed cells, CPXV-BR–infected OP9 cells were
treated with nothing, vehicle alone, or brefeldin A (Fig. 1 D).

Treatment with brefeldin A, but not its ethanol vehicle, prevented OMCP reactivity from appearing in the supernatant. Accordingly, OMCP accumulated in brefeldin A–treated
cell lysates. No supernatant reacted with preimmune serum.
The basis of the two OMCP bands secreted by OP9 cells
is unknown.

Figure 2. OMCP binds huNKG2D and muNKG2D. (A) Ba/F3 cells
expressing EGFP only (top), huNKG2D (middle), or muNKG2D (bottom)
were treated with nothing, SA-PE, or fluorescent tetramers. (B) Ba/F3
cells transduced with huNKG2D or muNKG2D were incubated with antiNKG2D mAb, isotype-matched mAb, irrelevant soluble protein, or soluble
ligand before staining with OMCPBR (rows 1 and 3) or OMCPMPX (rows
2 and 4) tetramers. (C) Ba/F3 cells transduced either with Thy1.1 (top)
or OMCP-Thy1.1 (middle and bottom) were treated with SA-APC or fluorescent tetramers. Untransduced (nongreen) Ba/F3 cells were included
as internal standards in A–C. Transduction vectors are dicistronic, with
EGFP in the second cistron. (D, 1) SPR assay of OMCPBR (0, 2, 5, 10, 20, 50,

100, 200, 500, and 1,000 nM) binding to immobilized muNKG2D. The
horizontal bar represents the OMCP injection, and the star represents the
time point used for KD fitting. (D, 2) Nonlinear curve fitting of steadystate SPR data reveals high affinity for muNKG2D and a good coefficient
of determination for the fit. (D, 3) One representative experiment out
of four showing kinetic data (black lines) and global fit (gray lines) of
OMCPBR (5, 10, 20, 50, and 100 nM) binding to muNKG2D. (D, 4) One representative experiment out of six showing kinetic data (black lines) and
global fit (gray lines) of OMCPBR (0.32, 0.63, 1.25, and 2.5 nM) binding
to huNKG2D. Note the very different dissociation kinetics between the
data in 3 and 4.
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Because it is not associated with a cell membrane, OMCP
cannot cluster its cognate receptor. Making the assumption
that most ZPXV immunomodulating proteins are immunosuppressive, we hypothesized that OMCP binds an activating
receptor, acting as a competitive antagonist.
OMCP binds to NKG2D with high affinity
Because NKG2D ligands adopt a class I–like fold (for review
see reference 8), we tested whether NKG2D is a receptor for
OMCP. To this end, Ba/F3 cells were transduced with defective dicistronic retroviruses encoding human NKG2D
(huNKG2D) and enhanced GFP (EGFP), mouse NKG2D
(muNKG2D) and EGFP, or EGFP alone.The NKG2D ectodomain was spliced to Ly49A transmembrane and intracellular domains to avoid the need for a signaling chain.
Transductants were then treated with fluorescent tetramers
and analyzed by flow cytometry. OMCP tetramers, but neither streptavidin-PE (SA-PE) alone nor irrelevant tetramers,
stained these transductants (Fig. 2 A, middle and bottom
rows). No tetramers stained EGFP-only transductants (Fig.
2 A, top row). Preincubation either with mAb against NKG2D
or with recombinant NKG2D ligands inhibited the interactions between OMCP tetramers and NKG2D transductants;
however, preincubation either with isotype control mAb or
with irrelevant recombinant protein failed to inhibit these interactions (Fig. 2 B). The origin of two distinct transductant
populations in certain purified cell preparations is unclear. To
exclude an artifact arising from a joint binding surface presented by OMCP and SA, the inverse experiment was also
performed. muNKG2D tetramers stained Ba/F3 transductants expressing chimeric OMCP-Thy1.1 on the cell surface
but not cells expressing only Thy1.1 (Fig. 2 C). Thus, OMCP
is a virally encoded NKG2D ligand.
We hypothesized that OMCP blocks the interaction between NKG2D and its target cell–expressed ligands. If so, it
should bind NKG2D with high affinity to overcome the
multivalency of cell-surface ligands at reasonable protein
concentrations. We performed surface plasmon resonance
(SPR) studies to determine the binding parameters of this
interaction, assuming a 1:1 binding model for (NKG2D)2/
OMCP. The KD of OMCPBR for immobilized muNKG2D
was 37 ± 6 nM (n = 3) by steady-state analysis at 20°C,
pH 7.5, and 150 mM NaCl (Fig. 2 D, 2). KD calculated from
kinetic analysis (i.e., KD = koff/kon; Fig. 2 D, 3) was similar:
28 ± 4 nM, with koff = 1.8 ± 0.1−2 s−1 and kon = 6.8 ± 1.2 ×
105 M−1s−1 (n = 4). These parameters are akin to those of the
higher affinity muNKG2D ligands H60 and RAE1ε (18, 19).
Curiously, affinity of OMCPBR for huNKG2D was strikingly
higher: KD = 168 ± 33 pM (n = 6), with the difference
largely caused by the lower koff (1.23 ± 0.12 × 10−4 s−1; Fig.
2 D, 4). Analogous experiments with OMCPMPX were not
performed because of the inability to obtain consistent specific
activity of the recombinant protein.
Next, C57BL/6 (B6) splenocytes were costained with NK
markers and OMCPBR tetramers (Fig. 3 A). NK and NKT
cells bound OMCPBR tetramers. Pretreatments with either
1314

anti-muNKG2D mAb (Fig. 3 A, lines 6) or the muNKG2D
ligand MULT1 (lines 8) inhibited binding to both cell types;
treatments with an isotype-matched mAb (lines 5) or an irrelevant protein had no effect (lines 7). Consistent with the
lack of NKG2D expression on resting mouse T cells (20),
OMCPBR tetramers failed to bind freshly isolated splenic T
cells. Splenocytes from three other strains of mice and (within
the limitations imposed by a lack of validated reagents) rats,
hamsters, guinea pigs, and voles also exhibited similar staining
with OMCPBR (unpublished data). This argues for the relevance

Figure 3. OMCP binds to mouse and human leukocyte subpopulations. (A) B6 splenocytes were stained with mAbs against NK markers
and OMCPBR tetramers. OMCPBR staining of cells in each gate is indicated
in histograms. Each histogram group shows unstained cells (lines 1),
cells stained with SA-APC alone (lines 2), irrelevant tetramers (lines 3),
OMCPBR tetramers (lines 4), or OMCPBR tetramers after pretreatment with
50 μg/ml of irrelevant hamster IgG (lines 5), equimolar anti-muNKG2D
(lines 6), 9.5 μM of irrelevant protein (lines 7), or equimolar MULT1
(lines 8). (B) Human PBMCs were stained with NK or T cell marker mAbs
and were tested for OMCP binding, as in A, for lines 1–4. Pretreatments
with 50 μg/ml of mouse IgG1 (lines 5) or equimolar anti-huNKG2D
mAb (lines 6) were also performed before staining with tetramers. Representative experiments are shown (n = 4). Vertical lines in histograms
represent the 99th percentile of staining for irrelevant tetramerstained cells.
ORTHOPOXVIRUS NKG2D ANTAGONIST | Campbell et al.
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of this work to rodents generally and the reservoir hosts of
ZPXV in particular (21, 22).
To explore the potential relevance of OMCP to orthopox
zoonoses, human PBMCs were tested for binding to OMCPBR
tetramers. Binding to human cells was essentially the same as
that to mouse cells, except that fresh CD8+ T cells bound
OMCPBR (Fig. 3B), consistent with the known expression of
NKG2D on these cells. Analogous to mouse splenocytes,
OMCP binding to human NK and NKT cells was blocked
by anti-huNKG2D mAb (Fig. 3 B, lines 6). Cumulatively,
these findings indicate that OMCP binds to NKG2D with
high affinity and in a manner competitive with the endogenous ligands of this receptor.
OMCP inhibits NKG2D-dependent killing as a
soluble antagonist
51Cr killing assays were performed using B6 lymphokine–
activated NK cells against RMA target cells. Control vector–
transduced RMA cells are relatively resistant to killing by
B6 NK cells because of syngeneic MHC class I expression
(Fig. 4 A, open squares) (23, 24). Expression of H60 by RMA
cells enhanced their susceptibility to killing by activated NK
cells in an NKG2D-dependent fashion (circles). NKG2D specificity was verified by inhibition of killing upon addition of
the high-affinity muNKG2D ligand MULT1 to the reaction
(unpublished data) (23). Recombinant OMCPBR at concentrations from 100 nM to 1 μM (open and closed triangles,
diamond, and closed squares) blocked RMA-H60 killing,
whereas 1 μM of irrelevant recombinant protein did not (Fig.
4 A, X). Similar results were obtained with fresh NK cells (not
depicted). This effect was not caused by down-regulation of
NKG2D, as exposure of B6 NK cells to 1 μM OMCPBR had
no effect on NKG2D expression (Fig. 4 B, lines 3 and 6).

Figure 4. OMCP inhibits muNKG2D-dependent killing by activated
NK cells but does not down-regulate NKG2D. (A) B6 IL2-activated NK
cells were used as cytotoxic effectors against transduced RMA cells in 4-h
51Cr release assays at effector/target ratios of 1:1, 3:1, or 10:1. There was
minimal killing of EGFP-only transductants (open squares). There was
effective NKG2D-dependent killing of H60 transductants (circles), but 1 μM
of irrelevant protein failed to inhibit NKG2D-dependent killing (X). However, OMCPBR at 1 (closed squares), 0.5 (diamond), 0.25 (closed triangle),
and 0.1 μM (open triangle) did effectively inhibit NKG2D-dependent
killing. Error bars were omitted to avoid crowding; coefficients of variation
for all data points were <10%. (B) B6 splenocytes were cultured for 24 h
with 1 μM of irrelevant protein (lines 1–3) or 1 μM OMCPBR (lines 4–6)
and stained with nothing (lines 1 and 4), isotype-matched mAb (lines 2
and 5), or anti-muNKG2D (lines 3 and 6). All histograms are gated on live,
CD3−, NK1.1+ cells. No differences in the scatter properties or viability of
cells was noted (not depicted). (C) Immunoblotting of OMCP was performed with known amounts of recombinant protein (left blot) or CPXVinfected OP9 supernatants (right blot). The former was used to quantitate
JEM VOL. 204, June 11, 2007

OMCP is likely a paracrine inhibitor of NKG2D function
OMCP binds NKG2D in a manner preventing recognition of
host ligands. This may be an important immune evasion strategy
during ZPXV infections. Given an adequate local OMCP
concentration around infected cells, inhibitory conditions
analogous to those in the killing assay of Fig. 4 A might be
attained. To measure the amount of OMCP produced during
infection, semiquantitative immunoblotting of infected cell
supernatants was performed using recombinant OMCP as a

the latter using a linear fit of OMCP densitometry to quantity (plot), as
detailed in Materials and methods. One experiment out of three is shown.
Xs represent mean calibration data, dots represent supernatant data, the
continuous line represents linear fit, and the dotted lines bound the 95%
confidence interval. (D) Ba/F3 cells were treated either with mock viral (left) or
CPXV-BR (right) preparations for 24 h. Cells were stained with nothing (lines 1),
SA-PE (rows 2), control tetramers (rows 3), or muNKG2D tetramers alone
(rows 4), as well as with 7-amino-actinomycin D. NKG2D binds infected cells,
indicating up-regulation of NKG2D ligands by CPXV-BR infection. The
percentage of positive cells corresponds to the percentage of productively
infected cells (not depicted). Vertical lines in the histograms (B and D) represent the 99th percentile of staining for irrelevant tetramer-stained cells.
1315

standard (Fig. 4 C). Protein was secreted at an average rate of
3,000 copies/cell/s during the viral incubation time. Assuming diffusion constants in interstitial fluid and basement
membrane of 10−7 and 5 × 10−9 cm2s−1, respectively (25),
this secretion rate reasonably allows inhibitory concentrations
of OMCP to develop around infected cells in situ given the
KD values of the NKG2D–OMCP interaction (26). We thus
propose a model in which secreted OMCP acts in paracrine
fashion to competitively antagonize the interaction between
NKG2D on cytotoxic effectors and induced ligands on infected
targets (Fig. 4 D). Because effective NKG2D cross-linking
cannot then take place, activation signals promoting granule
release are blunted, prolonging viral replication in infected
cells. This, especially at mucosal sites and in the skin, increases
the odds of transmission to another host, enhancing viral fitness.
Though NKG2D ligands shed into serum may cause systemic
receptor down-regulation (27), we disfavor this mode of action
for OMCP because soluble OMCP fails to down-regulate
NKG2D on mouse NK cells (Fig. 4 B).
Although certain virally encoded molecules are known to
impair NKG2D-mediated detection of infected cells (2–7),
OMCP is the first to target the receptor itself rather than its
ligands. Of greater note, OMCP serves as a pointer to a receptor specifically important to the interactions between ZPXV
and their hosts, guiding future studies of intercellular recognition events underlying cytotoxic immunity to these viruses.
MATERIALS AND METHODS
HMM analysis of sequences. The SAM software package (version 3.4) was
installed on a workstation running Redhat Linux 9. SAM is extensively documented at http://www.cse.ucsc.edu/research/compbio/papers/sam_doc/.
Using structural models of RAE1 (1jfm), ULBP3 (1kcg), MICA (1b3j),
MICB (1je6; for review see reference 8), and MULT1 (Fremont, D., personal
communication), multiple sequence alignment based on secondary structural
boundaries was generated and used as a seed for the target2k script with match
positions as constraints. Target2k in superfamily mode was applied to the
NCBI nr protein database. This alignment was then used by the buildmodel
script to produce HMMs of divergent class I–like protein sequences.
To tune parameters of the buildmodel and hmmscore procedures, a test
set of 26,000 irrelevant mouse cDNA sequences spiked with the cDNAs
encoding H60, m157, m154, and mill-1 was used. Parameters were chosen
based on assignment of lower expect values to the four spiked sequences than
to non–MHC-like sequences. The final model was built using w0.5 (global
scoring for model construction) default parameters. Sequence scoring was
ultimately performed using -sw2 (local) mode with a reverse-sequence null
model on reading frames >60 aa from raw genomic sequences of all viruses
(except CMV) available from the NCBI virus genome database as of February
2004. Sequence alignment was performed in SAM and formatted using
BoxShade software (version 3.2; available at http://www.ch.embnet.org/
software/BOX_doc.html).
Molecular cloning, expression, refolding, and SPR analysis of NKG2D
and mature OMCP. OMCPMPX (N3R; available from GenBank/EMBL/
DDBJ under accession no. NC_003310) and OMCPBR (V018; available
from GenBank/EMBL/DDBJ under accession no. AF482758) coding sequences were amplified from monkeypox Zaire 1979 DNA and CPXV-BR
DNA, respectively. Amplicons excluded the predicted leaders (Fig. 1) but
included C-terminal biotin ligase tags. Cloning and expression was performed as previously reported (19). OMCP and muNKG2D refolding, purification, biotinylation, characterization, and SPR analysis took place as
1316

previously described (19), except that the refolding time was extended to
>72 h. A huNKG2D protein from ...ESYCG to the C terminus, fused to
an N-terminal BirA tag, was similarly produced, except that refolding was
performed in 2.5 M proline/0.1 M Tris-Cl, pH 7.2/0.01% Na-azide/5 mM
of reduced glutathione/0.5 mM of oxidized glutathione, as previously
described (28). Regeneration of the huNKG2D/OMCP SPR chips was
performed using 30-s injections of 170 μM Triton X-100/0.5 M LiCl/20 mM
Na-citrate, pH 4.8.
Mice and cell culture. C57BL/6 mice were obtained from the National
Cancer Institute. RMA, Ba/F3, and activated NK cells were used as previously described (23, 29). B-SC-1 monkey kidney cells and OP9 marrow
fibroblastic cells were obtained from American Type Culture Collection.
Mouse work was approved by the Animal Studies Committee.
Retroviral constructs and generation of transduced cell lines.
HuNKG2D-expressing cells were produced by amplifying the huNKG2D
ectodomain sequence from FNQEV... to ...MQRTV, the muNKG2D ectodomain sequence from ...KETFQ to ...MKRAV, and the Ly49A transmembrane and intracellular domains from MSEQE... to ...SVLAI, with
primers such that the NKG2D N-termini overlapped with the Ly49A C terminus, and vice versa. These PCR products were PCR-spliced to produce
chimeric NKG2D-Ly49A. For OMCP-expressing cells, OMCP was fused
to the mature N terminus of Thy1.1. Full-length OMCPBR and OMCPMPX
were amplified with primers encoding a C-terminal linker of Ser(Gly)4Ser.
Thy1.1 was amplified from sequence QKVT... to ...DFISL. Primers amplifying the OMCP C termini overlapped with the N-terminal Thy1.1 primer,
and vice versa, allowing these amplicons to be spliced together. Full-length
Thy1.1 was amplified from sequence MNPAI... to ...DFISL. Amplicons
were used to produce retrovirally transduced cell lines sorted to homogeneity for expression of the transgenes, as previously described (23).
Antibodies and antiserum. The following antibodies were purchased
from eBioscience: anti-CD3 PE-Cy5, anti-CD4 FITC, mouse IgG1, antimuNKG2D–allophycocyanin (APC; clone CX5), and rat IgG1-APC. AntiCD3 FITC, anti-CD8 PE, anti-CD3 CyChrome, anti-CD56 PE, anti-NK1.1
PE, and anti-huNKG2D (clone 1D11), and hamster IgG were purchased
from BD Biosciences. Anti-muNKG2D (clone 3C7) has been previously
described (29). Rabbit OMCPBR antiserum was obtained from Washington
Biotechnology after immunization with refolded OMCPBR.
Viruses. CPXV-BR and VV were obtained from American Type Culture
Collection and were propagated in B-SC-1 cells using standard techniques.
Western blot analyses. 0.5 × 106 B-SC-1 cells/sample were infected with
CPXV-BR and/or VV at 5 PFU/cell in 1 ml of medium. The supernatant was
collected at 24 h, centrifuged at 13,000 g for 10 min, mixed with loading
buffer, resolved by SDS-PAGE, and transferred to nitrocellulose using standard
techniques. Membranes were incubated with 1:2,000 dilutions of OMCPBR
antiserum, preimmune serum, or anti–mouse actin (Chemicon), followed by
0.5 μg/ml of horseradish peroxidase–labeled goat anti–rabbit Ig antibody and
visualized with enhanced chemiluminescence (GE Healthcare).
Measurement of OMCP secretion was performed in sixwell plates by
infection of 300,000 OP9 cells with CPXV-BR (multiplicity of infection = 5)
for 20 h (>90% infected though intact cells at this point) in 0.85 ml of
medium. Immunoblots of culture supernatants and recombinant OMCP
standards were measured directly by fluorescence densitometry on a scanner
(Typhoon Trio) using ImageQuant software (both from GE Healthcare) and
uniform image rectangle background subtraction. Data of triplicate standards
were fit to a linear model of antibody binding to blotted OMCP using Prism
software (version 4; GraphPad) to obtain a standard line. Three experiments
with independent standards and infections, each in triplicate, were plotted
onto these lines to obtain the mean ± SD mass of OMCP secreted. Synthesis
rate (copies per second) was obtained from secreted mass as follows: rate =
mass × (NA)/[(20 h × 3,600 s/h) × (m.w.OMCP)].
ORTHOPOXVIRUS NKG2D ANTAGONIST | Campbell et al.
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Flow cytometry. B6 splenocytes were RBC cleared and passed through a
70-μm mesh. Human PBMCs were obtained from healthy donors using
Histopaque 1077 (Sigma-Aldrich). Cells were incubated with mAbs for
20 min on ice with gentle agitation after 10 min. For blocking experiments,
cells were incubated with proteins (50 μg/ml mAbs, 9.5 μM MULT1, or
125 μM ULBP4) for 15 min before the addition of tetramers. Both monobiotinyl-BSA and West Nile virus glycoprotein DIII (30) were used for irrelevant control tetramers with identical results. Live cell gates were based on
forward and side scatter plots and 7-amino-actinomycin D fluorescence.
Data were collected on a FACSCalibur (Becton Dickinson) and analyzed
with FloJo software (TreeStar, Inc.).
Chromium release assays. B6 NK cells stimulated with IL-2 for 7 d were
incubated for 10 min with media supplemented with nothing, MULT1,
OMCPBR, or irrelevant recombinant protein (BSA or West Nile virus glycoprotein DIII with identical results) at the concentrations indicated in the
figures. These were used in triplicate 51Cr killing assays, as previously
described (23).
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